AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results